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Nonalcoholic fatty liver disease (NAFLD) is an obesity-related condition affecting over
50% of individuals in some populations and is expected to become the number one cause
of liver disease worldwide by 2020. Common, robustly associated genetic variants in/near
five genes were identified for hepatic steatosis, a quantifiable component of NAFLD, in
European ancestry individuals. Here we tested whether these variants were associated with
hepatic steatosis in African- and/or Hispanic-Americans and fine-mapped the observed
association signals. We measured hepatic steatosis using computed tomography in five
African American (n5 3,124) and one Hispanic American (n5 849) cohorts. All analyses
controlled for variation in age, age2, gender, alcoholic drinks, and population substruc-
ture. Heritability of hepatic steatosis was estimated in three cohorts. Variants in/near
PNPLA3, NCAN, LYPLAL1, GCKR, and PPP1R3B were tested for association with
hepatic steatosis using a regression framework in each cohort and meta-analyzed. Fine-
mapping across African American cohorts was conducted using meta-analysis. African-
and Hispanic-American cohorts were 33.9/37.5% male, with average age of 58.6/42.6
years and body mass index of 31.8/28.9 kg/m2, respectively. Hepatic steatosis was 0.20-
0.34 heritable in African- and Hispanic-American families (P< 0.02 in each cohort).
Variants in or near PNPLA3, NCAN, GCKR, PPP1R3B in African Americans and
PNPLA3 and PPP1R3B in Hispanic Americans were significantly associated with hepatic
steatosis; however, allele frequency and effect size varied across ancestries. Fine-mapping
in African Americans highlighted missense variants at PNPLA3 and GCKR and redefined
the association region at LYPLAL1. Conclusion: Multiple genetic variants are associated
with hepatic steatosis across ancestries. This explains a substantial proportion of the
genetic predisposition in African- and Hispanic-Americans. Missense variants in PNPLA3
and GCKR are likely functional across multiple ancestries. (HEPATOLOGY 2013;58:966-975)
Abbreviations: CT, computed tomography; CEU, CEPH (Utah residents with ancestry from northern and western Europe); FamHS, Family Heart Study;
GCKR, Glucokinase Regulator; GENOA, Genetic Epidemiology Network of Arteriopathy; GOLD, Genetics of Obesity-related Liver Disease; GWAS, genome-wide
association study; h2, heritability; HDL, high-density lipoprotein; IRASFS, Insulin Resistance Atherosclerosis Family Study; JHS, Jackson Heart Study; JHS-ARIC,
Jackson Heart Study-Atherosclerosis Risk in Communities Study; LD, linkage disequilibrium; LYPLAL1, lysophospholipase-like 1; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis; NCAN, neurocan; PNPLA3, patatin-like phospholipase domain containing 3; PPP1R3B, protein phosphatase 1, regu-
latory subunit 3B; PUFAs, polyunsaturated fatty acids; SNPs, single nucleotide polymorphisms; SOLAR, sequential oligogenic linkage analysis routines; TG,
triglycerides.
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T
he prevalence of nonalcoholic fatty liver disease
(NAFLD) has increased with the rise in obesity
and is predicted to become the leading cause
of liver disease in the world by 2020.1 NAFLD is a
spectrum of diseases that includes liver steatosis (fat),
nonalcoholic steatohepatitis (NASH; fat and inflamma-
tion), and fibrosis/cirrhosis (scarring).2 NAFLD is cor-
related with central obesity, high levels of triglycerides
(TG), low levels of high-density lipoprotein (HDL)
cholesterol, high blood pressure, impaired glucose tol-
erance,3,4 and cardiovascular disease.5,6 Consequently,
the mortality related to both liver and nonliver causes
of death is predicted to reach epidemic proportions by
the end of the decade. Unfortunately, few medical
treatments presently exist for NAFLD. A better under-
standing of the pathophysiology of NAFLD will
improve the diagnosis, management, treatment, and
ultimately prevention of NAFLD.
Human genetic studies have provided new insights
into NAFLD. Computed tomography (CT) can be used
to reliably quantitate hepatic steatosis noninvasively in
population based samples. CT-measured hepatic steato-
sis has been found to be heritable (h25 0.26-0.27) in
European ancestry cohorts7 and shown to predict histo-
logical steatosis.8-11 Using a genome-wide association
study (GWAS) in 7,176 individuals of European ances-
try, the Genetics of Obesity-related Liver Disease
(GOLD) Consortium identified genetic variants that
reproducibly associated with hepatic steatosis in or near
the genes PNPLA3, LYPLAL1, PPP1R3B, NCAN, and
GCKR.7 Interestingly, the prevalence of NAFLD and
metabolic disease varies among ancestries.12,13 In partic-
ular, Hispanic Americans have the highest prevalence of
NAFLD, whereas African Americans have the low-
est.14,15 Some of this variation may be influenced by
genetics.16 Since the correlation between single nucleo-
tide polymorphisms (SNPs), known as linkage disequili-
brium (LD), or the nonrandom association of alleles,
varies among ancestries it remains to be determined
which susceptibility variants are shared or divergent
across ancestries.
In the present study, we first determined the propor-
tion of observed variation in hepatic steatosis which can
be attributed to genetic factors (heritability) in African-
and Hispanic-American families. We then aimed to rep-
licate, for the first time, the effects of multiple variants
in or near PNPLA3, GCKR, NCAN, PPP1R3B, and
LYPLAL1, which were robustly associated with hepatic
steatosis in European ancestry individuals, and summar-
ized the effects by performing a meta-analysis. Finally,
using GWAS data we fine-mapped the association signal
at these loci in African Americans in an effort to iden-
tify the putative causal variant(s).
Materials and Methods
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Network of Arteriopathy (GENOA19; African Ameri-
cans), and Family Heart Study (FamHS20; African
Americans) (Supporting Table 1).
Outcome Variable and Covariates
In each cohort hepatic steatosis was measured by
CT scanning using a standardized protocol. Either a
phantom (JHS, GENOA, and FamHS) or spleen den-
sity (IRASFS) was used to adjust attenuation values as
part of quality control. Details of the protocol can be
found in Supporting Table 2. Age, gender, and alcohol
intake was self-reported.
Genotyping
Details of the genotyping methods, quality control, and
imputation procedures used in each participating cohort
are shown in the Supporting Tables 3 and 4. Briefly, the
genotypes of index variants from European ancestry popu-
lations in patatin-like phospholipase domain containing 3
(PNPLA3; rs738409), protein phosphatase 1, regulatory
subunit 3B (PPP1R3B; rs4240624), neurocan (NCAN;
rs2228603), glucokinase regulator (GCKR; rs780094),
and lysophospholipase-like 1 (LYPLAL1; rs12137855)
were determined by array coupled with imputation (Affy-
metrix Human Chip v. 6.0: JHS, JHS-ARIC, and
GENOA; Illumina 1M-Duo v. 3.0: FamHS) or de novo
(Sequenom: IRASFS) genotyping.
Statistical Analysis
Heritability Determination. Cohort-specific esti-
mates of heritability for hepatic steatosis were obtained in
both African- (IRASFS, GENOA, and FamHS) and
Hispanic-American (IRASFS) families. While the amount
of alcohol consumption was generally low across samples,
it was nonnegligible; therefore, each study adjusted he-
patic steatosis values for the reported number of drinks
per week. Estimates of population substructure were
obtained from principal components derived from ge-
nome-wide data in African Americans and ancestry in-
formative markers in Hispanic Americans. In each cohort,
hepatic steatosis was inverse normally transformed to
reduce the impact of outliers and deviations from normal-
ity and thus standardize the phenotype in preparation for
meta-analysis. Hepatic steatosis was adjusted for age, age2,
gender, alcohol intake, and population substructure.
Thus, heritability calculations reflect the “residual” herit-
ability after controlling for covariates. Heritability esti-
mates were computed using a variance component
procedure implemented in sequential oligogenic linkage
analysis routines (SOLAR).21
Association Analyses. In each cohort, hepatic steato-
sis was inverse normally transformed. Cohort-specific
association analyses were performed in family-based sam-
ples accounting for family structure using either a random
effects model (IRASFS; SOLAR21) or a mixed linear
effects model (GENOA and FamHS, R) (Supporting Ta-
ble 5). Association analyses in JHS were carried out using
regression. Analyses were adjusted for age, age2, gender,
alcohol intake, and principal component estimates of
ancestry. Meta-analysis by race and overall was performed
using the inverse variance weighted method as imple-
mented in METAL (http://www.sph.umich.edu/csg/abe-
casis/metal/). For significance, a meta-analysis P< 0.01
Table 1. Characteristics of Study Populations
EA Meta-analysis
AA Cohorts
IRASFS HAFamHS GENOA IRASFS JHS JHS-ARIC
Demographics
N (% male) 7,227 (45.4) 622 (34.2) 555 (24.9) 364 (38.1) 1,180 (38.9) 403 (27.5) 849 (37.5)
Mean age (SD), years 62.8 (6.3) 53.4 (10.8) 69.0 (7.9) 43.6 (13.7) 55.5 (9.9) 69.9 (5.0) 42.6 (13.9)
Median drinks per week
(P25, P75)*
0-3 0 (0, 1) 0 (0,0) 0.23 (0, 2.8) 0.9 (0.1, 3.9) 0.6 (0.1, 2.0) 0.23 (0, 2.8)
Never drinkers (%) 2,436 (37.7) 349 (68.3) 430 (77.5) 170 (46.7) 611 (51.8) 128 (31.7) 398 (47.0)
Mean body mass index
(SD), kg/m2
27.5 (0.6) 32.7 (7.4) 32.7 (7.3) 29.9 (6.6) 32.1 (6.5) 30.7 (6.0) 28.9 (6.1)
CT attenuation
Reference Spleen and
phantom HD
Phantom HD Phantom HD Spleen Phantom HD Phantom HD Spleen
Median hepatic
steatosis,
HU (P25, P75)*
60-68 61.6 (56.3,
65.6)
60.2 (56.0,
65.7)
57.5 (52.8,
61.1)
60.1 (54.8,
64.5)
61.4 (55.7,
65.5)
55.5 (45.4,
60.5)
*Range of median values among EA studies.
Abbreviations: AA, African American; ARIC, Atherosclerosis Risk in Communities; CT, computed tomography; EA, European Ancestry; FamHS, Family Heart Study;
GENOA, Genetic Epidemiology Network of Arteriopathy; HA, Hispanic American; HU, Hounsfield Units; IRASFS, Insulin Resistance Atherosclerosis Family Study; JHS,
Jackson Heart Study; P25, 25th percentile; P75, 75th percentile; Phantom HD, high density external hydroxyapetite CT control; SD, standard deviation.
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(Bonferroni correction for five tests) was considered signif-
icant while values less than 0.10 with consistent direction
of effect were considered trending.
To facilitate fine-mapping of these five loci, geno-
typed and imputed data were extracted from GWAS
datasets (JHS, JHS-ARIC, GENOA, and FamHS)
(Supporting Table 5). The region of interest for each
locus was defined using an LD threshold of r2> 0.1
from the index variant in the European ancestry meta-
analysis as estimated from the HapMap European
(CEU) population. These regions are most likely to
harbor causal variants in LD with the index variant
reported in the original study in those of European
ancestry.7 Variants from individual cohorts were
included in the meta-analysis if they had a minor allele
frequency 1% and imputation quality of r2 0.3.
Furthermore, SNPs needed to be present in three
out of four cohorts to be included in analyses. Meta-
analysis was performed using the inverse variance
weighted method as implemented in METAL (http://
www.sph.umich.edu/csg/abecasis/metal/).
Results
The study sample characteristics are shown in Table
1. In general, subjects were middle-aged, although
subjects from IRASFS were younger (mean age 43
versus 53-70 years in other cohorts). Despite their
younger age, the mean CT liver attenuation of His-
panic Americans trended towards being lower—indi-
cating increased hepatic steatosis—than subjects of
African ancestry. The alcohol consumption was gener-
ally low across cohorts.
Estimates of heritability of hepatic steatosis are
shown in Table 2. Two of the African American
cohorts showed slightly higher heritability (0.306 0.08
and 0.346 0.10 in GENOA and FamHS, respectively),
while the African- and Hispanic-American subjects
from IRASFS showed lower heritability (0.226 0.12
and 0.206 0.07, respectively). These data indicate that
liver fat in adult subjects is moderately heritable across
the cohorts in the current study and justifies exploring
the contribution of genetic variants.
The summary of association evidence for loci
replicated from the previously published meta-
analysis of European ancestry in African- and Hispanic-
American individuals is shown in Table 3 and Figs. 1
and 2 (cohort-specific results for African Americans are
shown in Supporting Fig. 1 and Supporting Table 6).
Using the criterion P< 0.01 (Bonferroni correction for
five tests), three of the variants—PNPLA3 (rs738409),
PPP1R3B (rs4240624), and NCAN (rs2228603)—were
Table 2. Heritability Estimates for Hepatic Steatosis in African-American and Hispanic-American Cohorts
Cohort N Subjects N Families Ascertainment Age Range (Years) Heritability SE P Value
African Americans
FamHS 622 214 Families of hypertensive probands 30-83 0.34 0.10 1.90E-04
GENOA 555 410 Sibs of hypertensive probands 40-98 0.30 0.08 4.00E-03
IRASFS 364 41 Families of T2D, IGT and NGT probands 18-80 0.22 0.12 1.10E-02
Hispanic Americans
IRASFS 849 86 Families of T2D, IGT and NGT probands 18-81 0.20 0.07 7.00E-05
Abbreviations: FamHS, Family Heart Study; GENOA, Genetic Epidemiology Network of Arteriopathy; IRASFS, Insulin Resistance Atherosclerosis Family Study; T2D,
type 2 diabetes; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
Table 3. Association Summary Statistics for the Five Hepatic Steatosis Loci
Locus EA Meta-analysis N5 7,176 AA Meta-analysis N5 3,124 IRASFS HA N5 839 ALL Meta-analysis N5 11,139
SNP ID Chr (Position)
Nearest
Gene EA EAF
Beta
(SE) P Value EAF
Beta
(SE) P Value EAF
Beta
(SE) P Value EAF
Beta
(SE) P Value
rs738409 22 (42656060) PNPLA3 G 0.23 0.26 (0.02) 4.30E-34 0.15 0.31 (0.04) 5.08E-18 0.40 0.28 (0.05) 1.97E-07 0.23 0.27 (0.02) 1.64E-61
rs2228603* 19 (19190924) NCAN T 0.07 0.24 (0.03) 1.22E-11 0.02 0.32 (0.11) 4.28E-03 0.04 20.27 (0.14) 0.062 0.07 0.22 (0.03) 2.78E-15
rs12137855 1 (217515001) LYPLAL1 C 0.79 0.08 (0.02) 1.06E-04 0.85 20.01 (0.03) 0.76 0.82 20.07 (0.07) 0.32 0.81 0.05 (0.02) 3.06E-03
rs780094 2 (27594741) GCKR T 0.39 0.06 (0.02) 2.56E-04 0.18 0.06 (0.03) 0.058 0.38 0.10 (0.06) 0.088 0.33 0.06 (0.02) 1.09E-04
rs4240624 8 (9221641) PPP1R3B A 0.92 0.29 (0.03) 3.68E-18 0.81 0.15 (0.03) 3.27E-06 0.81 0.15 (0.07) 0.025 0.86 0.22 (0.02) 2.26E-25
*rs2228603: N5 1,947 for AA meta-analysis and N5 9,965 for ALL meta-analysis.
The total variances explained across the five loci were: 4.76%, 3.63%, and 5.64%, in individuals of European Ancestry, African Americans, and Hispanic Ameri-
cans, and 4.56% of variance in all individuals combined.
Abbreviations: EA, European Ancestry; AA, African American; IRASFS, Insulin Resistance Atherosclerosis Family Study; HA, Hispanic American; Chr, chromosome;
Position (Mb), Position in megabases using build 35; EA, effect allele; EAF, effect allele frequency; Beta, regression coefficient for the coded allele on hepatic stea-
tosis (measured using liver attenuation controlled for scan penetrance) per one standard deviation increase in rank equivalent to 1 standard deviation increase in
normally transformed trait value; SE, standard error of the beta; P Value, P Value of association.
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Fig. 1. Forest plot of the effect for hepatic steatosis index variants in European ancestry, African American, and Hispanic American populations.
For each race and a pooled analysis, the effect allele (EA) and frequency (EAF) are listed with the corresponding P Value (p), beta value (beta),
and 95% confidence interval (95% CI) for association with hepatic steatosis adjusting for age, age2, gender, alcoholic drinks, and population sub-
structure. Values greater than zero indicate an increase in the amount of hepatic steatosis. The solid vertical line represents no effect (beta5 0).
Fig. 2. Allele frequency distribution for hepatic steatosis index variants in European ancestry, African American, and Hispanic American popula-
tions. For each index variant, the effect allele is listed with a corresponding bar denoting the frequency observed in European ancestry (gray),
African American (white), and Hispanic American (black) populations as well as in the pooled analysis (dark gray).
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significant in the African American meta-analysis, with
allele frequencies and effect direction consistent with
the European ancestry results. PNPLA3 (rs738409) also
displayed significant association in the Hispanic
American study; however, the other two loci trended to-
ward significance and the association with NCAN
(rs2228603) was in the opposite direction, suggesting
that, if real, it would have a small protective effect in
Hispanic Americans, contrary to its fat-increasing effect
in other ancestry groups. This was the only locus
to have a significant P-value of heterogeneity across
ancestries (data not shown). GCKR (rs780094) dis-
played trending evidence of association (P< 0.10), and
although it did not reach significance in the African- or
Hispanic-American analyses, the direction and magni-
tude of the effect of the T allele was consistent with the
European ancestry findings, indicating a general consis-
tency across racial groups. LYPLAL1 (rs12137855) was
not significant in either African- or Hispanic-Americans
and despite comparable allele frequencies.
Meta-analysis of all available data across racial
groups bears out these trends supporting a consistent
role for variants near PNPLA3, PPP1R3B, and NCAN
with diminished evidence of association with GCKR
and LYPLAL1. However, the effect of the GCKR vari-
ant remains consistent, but modest, across all racial
groups and the lack of significance may be more an
issue of power. In contrast, the results indicate lack of
evidence for association of the variant near LYPLAL1
in African- and Hispanic-Americans.
The variance explained varied by locus and ancestry
(Fig. 3). In particular, PNPLA3 (rs738409) explained
the most variance in Hispanic Americans (3.31%), less
in African Americans (2.58%), and the least in Euro-
pean ancestry populations (2.39%); this could be
attributed to differences in the allele frequency of the
fatty liver promoting variant (G) as the effect size of
this allele was roughly equivalent across ancestries.
PPP1R3B (rs4240624), in contrast, had an effect size
in European ancestry populations that was twice that
in the other ancestries, whereas its frequency was
roughly the same across the three groups. As a conse-
quence, this variant explained a higher proportion of
the variance in European ancestry individuals (1.24%)
than African- and Hispanic-Americans (0.76% and
0.69%, respectively). GCKR (rs780094) had the same
effect across ancestries but its frequency in African
Americans was half of that in European ancestry indi-
viduals and Hispanic Americans, which were about
equal (Fig. 2). The LYPLAL1 (rs12137855) association
signal was not significant in African- and Hispanic-
Americans, making the slight differences in the actual
Fig. 3. Weighted average of the variance explained by each SNP for European ancestry, African American, and Hispanic American populations.
For each index variant, the corresponding bars represent the proportion of variance explained in European ancestry (gray), African American
(white), and Hispanic American (black) populations as well as in the pooled analysis (dark gray).
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association signals across ancestries difficult to inter-
pret; further evaluation of this locus in Hispanic
Americans by fine mapping is warranted. Finally,
NCAN (rs2228603) had a strong effect in European
ancestry individuals and African Americans but possi-
bly goes in the opposite direction in Hispanic Ameri-
cans (Fig. 1). The total variances explained across the
five loci were: 4.76%, 3.63%, and 5.64% in individu-
als of European ancestry, African Americans, and His-
panic Americans, and 4.56% of variance in all
individuals combined.
Fine-mapping of these loci in African Americans
revealed that the strongest associating variants at
PNPLA3 and GCKR were missense variants (rs738409,
Fig. 4A,B and rs1260326, Fig. 4C,D, respectively).
Analysis of the PPP1R3B locus revealed a similar pat-
tern of association as seen in European ancestry indi-
viduals (Supporting Fig. 2A,B). The association signal
at LYPLAL1 in African Americans (rs10449309,
P5 0.00223) appears to be distinct from that observed
in European ancestry populations and is separated by a
recombination hotspot (Fig. 4E,F). Results from fine-
mapping of the NCAN (Supporting Fig. 2C,D) locus
revealed a differential pattern of LD with no addi-
tional variants showing stronger association.
Discussion
Here we explored the genetic underpinnings of
NAFLD across ancestries. The prevalence of this con-
dition has been shown to vary, with individuals of His-
panic ancestry having more NAFLD than individuals
of European ancestry, who have higher prevalence of
NAFLD than individuals of African ancestry. The
underlying causes of these differences remain to be
determined. Here we test whether previously identified
genetic variants contributing to hepatic steatosis, a
quantifiable component of NAFLD, yield similar
effects in different racial populations.
We found evidence that hepatic steatosis was 20%-
34% heritable in African- and Hispanic-Americans
families after accounting for variation associated with
age, age2, gender, alcohol intake, and population sub-
structure. This was similar to what has been reported
in European ancestry populations in previous studies
of the same quantitative component of NAFLD,7 in
children of Hispanic ancestry using hepatic steatosis
quantified from liver biopsies or magnetic resonance
scans,22 and in the IRASFS, in which the heritability
of liver density without control for scan penetrance
(spleen) yielded modestly greater heritability estimates
among African Americans (h25 0.20) and Hispanic
Americans families (h25 0.35).23 These results rein-
force that development of NAFLD is partially geneti-
cally influenced.
We also tested whether specific variants that associate
with hepatic steatosis in European ancestry individuals
associated with this phenotype in African- and His-
panic-Americans. We found that variants in or near
PNPLA3 (rs738409), PPP1R3B (rs4240624), and
NCAN (rs2228603) were significantly associated in
African Americans and PNPLA3 (rs738409) in His-
panic Americans. Interestingly, the effect size of
PNPLA3 (rs738409) was similar across the ancestries
but the frequency of the effect allele (G) varied so that
the variance explained in Hispanic Americans was
higher than in European ancestry individuals than in
African Americans and consistent with the observed
prevalence of NAFLD. This trend has been previously
noted.16 However, this was not a universal trend across
the variants. PPP1R3B (rs4240624) had an effect size
in European ancestry individuals that was twice that in
the other ancestries, whereas its frequency was roughly
the same across the three groups. As a consequence, this
variant explains a higher proportion of the variance in
European than African than Hispanic ancestry individu-
als. The association signal was in the same region in
European ancestry and African American individuals,
suggesting that a difference in LD across populations is
not likely to explain this difference in effect. This sug-
gests other factors may be important in determining the
effect of this variant across ancestries (see below). The
effect of GCKR (rs780094) was similar across ancestries
but its frequency in African Americans was half of that
in European ancestry and Hispanic American individu-
als (which were about equal). LYPLAL1 (rs12137855)
had, if anything, a small, or arguably no effect in Afri-
can- and Hispanic-Americans. This may, in part, be
due to the signal not being present or being different
(see fine-mapping) in African- and Hispanic-Americans;
further evaluation of this locus in Hispanic Americans
by fine-mapping is warranted. Finally, NCAN
(rs2228603) has a strong effect in European ancestry
individuals and African Americans; however, the direc-
tion of effect of the alleles is in the opposite direction
in Hispanic Americans. Whether this observation is due
to differences in LD, power, or interactions with other
genes and/or environments in Hispanic Americans com-
pared with those of other ancestries remains to be eluci-
dated. Since the fatty liver promoting allele is low
frequency in all ancestries and particularly rare in Afri-
can Americans, sequencing may be required to find the
causal variant(s) at this locus.
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We took advantage of LD differences between
ancestries to fine-map the five NAFLD associated loci
in individuals of African ancestry. We found that at
PNPLA3 (rs738409) and GCKR (rs1260326), among
the strongest associated variants in African Americans,
were missense variants that have been shown to have
Fig. 4. Regional plots of loci robustly associated with NAFLD in European ancestry population and fine-mapped in the African American popu-
lation. (A) PNPLA3 in African Americans, (B) PNPLA3 in European Americans, (C) GCKR in African Americans, (D) GCKR in European Americans,
(E) LYPLAL1 in African Americans, (F) LYPLAL1 in European Americans. The variant most robustly associated is denoted in purple annotated by
SNP ID with additional genotyped and imputed SNPs passing study-specific quality controls. SNPs are plotted with their meta-analysis P Values
as a function of position (hg19). Shape of the data point is indicative of function, i.e., nonsynonymous (!) and no annotation (), and color
indicates LD (r2) with the previously identified variant taken from HapMap (red, r25 0.8-1.0; yellow, r25 0.6-0.8; green, r25 0.4-0.6; cyan,
r25 0.2-0.4, and blue, r2< 0.2). Estimated recombination rates (HapMap) reflect the local LD structure. Gene annotations were taken from the
University of California Santa Cruz genome browser.
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functional consequences.24,25 Recent reports propose that
PNPLA3 helps to break down triglycerides in the liver.26
Interestingly, mice lacking PNPLA3 do not develop
fatty liver,27 whereas overexpression of the mutant (but
not wildtype) PNPLA3 in mouse liver does lead to ste-
atosis,24 suggesting that the variant in PNPLA3 may
exert its effects via a gain of function. GCKR sequesters
glucose kinase (GK) in the nucleus and is also a com-
petitive inhibitor of GK, preventing it from phospho-
rylating glucose.25,28 Phosphorylated glucose is a
precursor to formation of glycerol and of fatty acids,
both of which are needed for formation of triglycer-
ides. The rs1260326 variant eliminated GCKR activity
and results in disinhibition of GK leading to glucose to
triglyceride shifts.25,28 Therefore, our data combined
with the above findings suggest that these associated
variants may be functional across ancestries.
The differences in the variance explained by
PNPLA3 (rs738409) across ancestries may be due, in
part, to differences in allele frequency but may also be
due to gene-environment interactions. In FamHS it
has been found that PNPLA3 (rs738409) has an inter-
action with visceral adipose tissue and gender, having
more of an effect in women and in those with higher
levels of visceral fat.29 In the IRASFS, African Ameri-
cans had lower visceral adipose tissue than Hispanic
Americans which may, in part, account for the lower
effect of PNPLA3 on hepatic steatosis.30 Further, in a
study of 127 children and adolescents, researchers
found that the ratio of n-6 to n-3 polyunsaturated
fatty acids (PUFAs) interacted with the GG genotype
at rs738409 in PNPLA3 promoting hepatic steatosis.
This suggests a nonadditive increase in hepatic steatosis
in individuals with the GG genotype at rs738409
when consuming higher n-6 versus n-3 PUFAs.31
Whether this or other dietary interactions account for
some of the effects of PNPLA3 (rs738409) on hepatic
steatosis across ancestries remains to be determined.
We further fine-mapped the signal at LYPLAL1
and found that the strongest association signal in
individuals of African ancestry (rs10449309) may not
be the same as in European ancestry populations
(rs10779342). Indeed, the strongest association signal
was distal of the nearby recombination interval in Afri-
can Americans, whereas in European ancestry individu-
als it was proximal to this landmark. However, there
could be two signals near LYPLAL1 in European
ancestry populations, one of which corresponds to the
signal seen in African Americans. This signal may be
better defined with increased European ancestry sample
sizes in future studies. Alternatively, it may also be bet-
ter defined through functional experiments.
A limitation of our study is that it uses cross-sec-
tional cohort data that may not accurately depict
genetic risk over time, which has been shown to be cu-
mulative and larger than in cross-sectional designs.32
The analyses presented herein mirror those of the origi-
nal report7 with covariates that are not hypothesized to
be in the causal pathway between the SNP and develop-
ment of NAFLD. It remains to be determined whether
the effects of our variants on variation in NAFLD may
be mediated through changes in insulin resistance, obe-
sity, serum lipid levels, or other mechanisms. Formal
Mendelian randomization experiments can be carried
out in the future to help elucidate these possibilities.
Additionally, Hispanic Americans were only represented
by one study and will require replication in more
cohorts to verify effects with increased power. Finally,
this was a study of hepatic steatosis and the effects of
these variants on developing nonalcoholic steatohepatitis
and/or fibrosis remain to be determined.
This is the largest study to date assessing the effects
of genetic variants across ancestries for hepatic steato-
sis, a quantifiable component of NAFLD. This report
confirms the effects of variants previously identified in
European ancestry populations in African and His-
panic populations. In addition, fine-mapping efforts in
the African American population have identified a
novel association region in LYPLAL1 and implicated a
missense variants in GCKR (rs1260326) and PNPLA3
(rs738409) in NAFLD pathology. These results dem-
onstrate how cross-ancestry comparisons of association
results can help fine-map association signals. This is
the first study to show heterogeneity of genetic effects
across ancestries suggesting that other elements besides
genotype may affect the expressivity of these variants.
Clinically, our findings shows that genetic predisposi-
tion to disease can vary across ancestries and in this
way may contribute to health disparities between
groups. Further, by characterizing the mechanisms by
which these genetic variants act across ancestries we
may be able to identify the genes and biological path-
ways that they act through so that we can target these
to prevent or treat this disease more effectively in the
future. We have also identified the likely causal var-
iants that predispose to NAFLD across ancestries at
two loci which may be used as part of a cumulative
genetic NAFLD risk marker panel in the future.
Finally, although we show that development of
NAFLD can be genetically influenced, much of the
variation in the development of the trait is not genetic
and thus leaves much hope and promise for being able
to abrogate the disease in the future by changing envi-
ronmental influences.
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